[go: up one dir, main page]

DK3094731T3 - Saccharidmodificerede nukleinsyremolekyler - Google Patents

Saccharidmodificerede nukleinsyremolekyler Download PDF

Info

Publication number
DK3094731T3
DK3094731T3 DK15700464.9T DK15700464T DK3094731T3 DK 3094731 T3 DK3094731 T3 DK 3094731T3 DK 15700464 T DK15700464 T DK 15700464T DK 3094731 T3 DK3094731 T3 DK 3094731T3
Authority
DK
Denmark
Prior art keywords
saccharide
nucleic acid
acid molecules
modified nucleic
modified
Prior art date
Application number
DK15700464.9T
Other languages
English (en)
Inventor
Thomas Carell
Original Assignee
Baseclick Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baseclick Gmbh filed Critical Baseclick Gmbh
Application granted granted Critical
Publication of DK3094731T3 publication Critical patent/DK3094731T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C12N15/8218Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8201Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
    • C12N15/8206Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation by physical or chemical, i.e. non-biological, means, e.g. electroporation, PEG mediated
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • C12N2310/141MicroRNAs, miRNAs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
DK15700464.9T 2014-01-15 2015-01-15 Saccharidmodificerede nukleinsyremolekyler DK3094731T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14151255 2014-01-15
PCT/EP2015/050685 WO2015107115A1 (en) 2014-01-15 2015-01-15 Saccharide-modified nucleic acid molecules

Publications (1)

Publication Number Publication Date
DK3094731T3 true DK3094731T3 (da) 2019-08-05

Family

ID=49989536

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15700464.9T DK3094731T3 (da) 2014-01-15 2015-01-15 Saccharidmodificerede nukleinsyremolekyler

Country Status (14)

Country Link
US (1) US10751425B2 (da)
EP (1) EP3094731B1 (da)
JP (1) JP6584412B2 (da)
CN (1) CN105899666B (da)
BR (1) BR112016014162A2 (da)
DK (1) DK3094731T3 (da)
ES (1) ES2742102T3 (da)
HR (1) HRP20191471T1 (da)
HU (1) HUE045086T2 (da)
LT (1) LT3094731T (da)
PL (1) PL3094731T3 (da)
PT (1) PT3094731T (da)
SI (1) SI3094731T1 (da)
WO (1) WO2015107115A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015088990A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
JP2019520342A (ja) 2016-06-02 2019-07-18 サノフイSanofi グルコース感知タンパク質に結合することができる薬剤および部分のコンジュゲート
EP3554551A1 (en) * 2016-12-14 2019-10-23 University College Cork-National University of Ireland, Cork Cyclodextrin conjugates
EP3728602A1 (en) * 2017-12-21 2020-10-28 baseclick GmbH Click-modified mrna
CA3089276A1 (en) * 2018-02-17 2019-08-22 Arrowhead Pharmaceuticals, Inc. Trialkyne linking agents and methods of use
US12065458B2 (en) 2018-02-17 2024-08-20 Arrowhead Pharmaceuticals, Inc. Trialkyne linking agents and methods of use
CN114901316B (zh) * 2019-08-05 2024-02-13 宝利普拉斯生物转染公司 包含接枝到阳离子聚合物上的三唑化合物的用于将核酸分子转染到细胞中的组合物及其应用
CN111041025B (zh) 2019-12-17 2021-06-18 深圳市瑞吉生物科技有限公司 基于结合N-乙酰半乳糖胺多肽的mRNA靶向分子及其制备方法
CN112111524B (zh) * 2020-01-10 2024-02-27 深圳瑞吉生物科技有限公司 mRNA-GalNAc靶向分子的制备方法及其体内递送系统和应用
CN111744019B (zh) * 2020-07-01 2023-08-04 深圳瑞吉生物科技有限公司 基于甘露糖的mRNA靶向递送系统及其应用
WO2022094609A1 (en) * 2020-10-30 2022-05-05 Speer Tod Oligonucleotide-based therapeutics and uses thereof
WO2022226396A1 (en) * 2021-04-23 2022-10-27 Ganna Bio, Inc. Glycan modified nucleic acids, methods of preparation, and therapeutic uses
CA3232387A1 (en) * 2021-09-13 2023-03-16 Ganna Bio, Inc. Glycan conjugate compositions and methods
WO2023233395A1 (en) * 2022-05-30 2023-12-07 Nurexone Biologic Ltd. Compositions and methods for loading extracellular vesicles
CN115487308B (zh) * 2022-09-29 2024-09-27 北京大学 反义核酸糖基缀合物及其制备方法和在肝癌治疗中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2352509T3 (es) 2005-05-02 2011-02-21 Baseclick Gmbh Nuevas estrategias de marcaje para la detección sensible de analitos.
JP2007044012A (ja) 2005-08-12 2007-02-22 Konan Gakuen 葉の水分蒸散を調節する方法、及び植物の耐乾燥性を向上させる方法
AU2008290217B2 (en) * 2007-08-20 2013-09-05 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
EP4074344A1 (en) * 2007-12-04 2022-10-19 Arbutus Biopharma Corporation Targeting lipids

Also Published As

Publication number Publication date
SI3094731T1 (sl) 2019-10-30
HRP20191471T1 (hr) 2019-11-15
BR112016014162A2 (pt) 2018-01-09
WO2015107115A1 (en) 2015-07-23
US10751425B2 (en) 2020-08-25
HUE045086T2 (hu) 2019-12-30
PT3094731T (pt) 2019-09-04
PL3094731T3 (pl) 2019-10-31
US20160333364A1 (en) 2016-11-17
EP3094731A1 (en) 2016-11-23
JP6584412B2 (ja) 2019-10-02
CN105899666A (zh) 2016-08-24
JP2017504322A (ja) 2017-02-09
EP3094731B1 (en) 2019-07-17
LT3094731T (lt) 2019-10-25
CN105899666B (zh) 2020-10-09
ES2742102T3 (es) 2020-02-13

Similar Documents

Publication Publication Date Title
DK3341482T3 (da) Kunstige nukleinsyremolekyler
DK3433368T3 (da) Transreplikerende rna
DK4023249T3 (da) Nukleinsyrevacciner
SG11201704681QA (en) Artificial nucleic acid molecules
HUE042283T2 (hu) Antiszensz nukleinsav
HUE049405T2 (hu) Nukleáz-közvetített DNS-összeállítás
DK3234132T3 (da) Ligand-modificerede dobbeltstrengede nukleinsyrer
HUE047175T2 (hu) Eljárások nukleinsavak tanulmányozására
DK4023755T5 (da) Kunstige nukleinsyremolekyler til forbedret proteinudtrykkelse
DK3094731T3 (da) Saccharidmodificerede nukleinsyremolekyler
DK3129487T3 (da) Forbedrede nukleinsyrekonstruktioner til eukaryot genekspression
HK1244021A1 (zh) 核酸構建體
HK1243958A1 (zh) 核酸構建體
DK3188836T3 (da) Dna-syntese
DK3167044T3 (da) Mikrofluidindretning
DK3105250T3 (da) Multispecifikke iga-bindingsmolekyler
DK3351633T3 (da) Antisense-nukleinsyre
EP3156789C0 (en) BIOSENSOR
DK3341479T3 (da) LNA-G-Proces
DK3242685T3 (da) Cxcr4-bindende molekyler
DK3110442T3 (da) Modificerede meningokok-fhbp-polypeptider
EP3498724A4 (en) NUCLEIC ACID COMPLEX
DK2952752T3 (da) Afbøjnings-rørbøjning
EP3387414A4 (en) BIOSENSOR
IL249254A0 (en) Gene expression system